Related Experiment Video
Updated: May 14, 2026
06:38
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
Bioinformatics analysis reveals potential candidate drugs for HCC
Xiao-Bing Huang1, Jing Li, Lu Zheng
1Department of Hepatobiliary Surgery, Xinqiao Hospital, Third Military Medical University, 400037, NO.2 Xin Qiao Street, Sha Ping Ba District, Chongqing, People's Republic of China.
Pathology Oncology Research : POR
|January 24, 2013
Summary
This study identifies key genes and pathways in cirrhosis progression to hepatocellular carcinoma. Bioinformatics analysis revealed potential small molecule drugs for targeted cancer therapy.
Area of Science:
- Oncology
- Genomics
- Bioinformatics
Background:
- Cirrhosis is a significant risk factor for hepatocellular carcinoma.
- Understanding the molecular mechanisms driving this progression is crucial for effective treatment.
- Identifying therapeutic targets can lead to novel small molecule drug development.
Purpose of the Study:
- To analyze gene expression differences between cirrhosis and hepatocellular carcinoma using the GSE17967 dataset.
- To elucidate the molecular mechanisms underlying the progression from cirrhosis to hepatocellular carcinoma.
- To identify potential small molecule drugs that can interfere with this disease progression.
Main Methods:
- Differential gene expression analysis of the GSE17967 dataset.
- Pathway enrichment analysis to identify key biological processes.
- In silico drug screening and linkage analysis.
Main Results:
- Identified differentially expressed genes between cirrhosis and hepatocellular carcinoma.
- Highlighted specific sub-pathways critical to disease progression.
- Successfully linked known and novel small molecule drugs to potential therapeutic interventions.
Conclusions:
- Bioinformatics analysis is a powerful tool for understanding cirrhosis to hepatocellular carcinoma progression.
- The study identified candidate small molecule drugs for hepatocellular carcinoma treatment.
- Findings provide a basis for further experimental validation and drug development.
